This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Puma Biotech (PBYI) Q3 Loss Narrows, Nerlynx Pulls Stock Down
by Zacks Equity Research
Puma Biotech (PBYI) betters loss estimates in Q3. However, its only marketed drug, Nerlynx, disappoints with low sequential growth and as a result, shares take a hit.
Puma Biotech (PBYI) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Puma Biotech (PBYI) delivered earnings and revenue surprises of 65.42% and 13.82%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Puma Biotech (PBYI) Q3 Earnings Preview: What to Look Out For
by Zacks Equity Research
Puma Biotech (PBYI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Puma Biotech (PBYI) Rides High on Robust Nerlynx Performance
by Zacks Equity Research
Puma Biotech (PBYI) focuses on improving sales of its flagship and the only approved product Nerlynx. The drug's label expansion programs also appear promising.
Puma Biotech Gets EU Nod for Breast Cancer Drug Nerlynx
by Zacks Equity Research
Puma Biotech (PBYI) gains EU approval for Nerlynx as an extended adjuvant treatment in adult patients with early stage HER2-positive breast cancer.
The Zacks Analyst Blog Highlights: Amgen, Puma Biotechnology, MannKind, United Therapeutics and Vertex Pharmaceuticals
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Amgen, Puma Biotechnology, MannKind, United Therapeutics and Vertex Pharmaceuticals
Biotech Stock Roundup: AMGN, PBYI Get EC Nod for Their Drugs, MNKD Soars
by Zacks Equity Research
Drug approvals in Europe and other pipeline updates comprise some of the key developments in the biotech sector this week.
Puma Biotech (PBYI) Q2 Loss Narrows, Nerlynx Drives Sales
by Zacks Equity Research
Puma Biotech (PBYI) posts narrower-than-estimated loss in Q2. Also, rapid growth of its only marketed drug, Nerlynx, boosts sales.
Puma Biotech (PBYI) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Puma Biotech (PBYI) delivered earnings and revenue surprises of 53.17% and 0.77%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Drug/Biotech Stock Q2 Earnings on Aug 9: PRGO, BDSI & More
by Zacks Equity Research
Several drug/biotech companies are set to report second-quarter results on Aug 9. Let's see how things are shaping up for their announcements.
What's in the Cards for Puma Biotech (PBYI) in Q2 Earnings?
by Zacks Equity Research
On Puma Biotechnology's (PBYI) second-quarter 2018 earnings call, investor focus will be on the sales figures of its only marketed drug Nerlynx.
Company News For Jun 27, 2018
by Zacks Equity Research
Companies In The News are: LEN,V,GE,PBYI
Puma Biotechnology's Shares Rise on Positive CHMP Trend Vote
by Zacks Equity Research
Puma Biotechnology's (PBYI) marketing application seeking approval for neratinib in breast cancer gets positive CHMP trend vote, following a negative opinion in February.
Biotech Stock Roundup: PBYI Soars, MACK Crashes, GILD's Biktarvy Gets EC Nod
by Zacks Equity Research
The biotech sector was in the news with a few hits and misses. Gilead's Biktarvy got approval in Europe while Puma Biotechology is also closer to breast cancer drug approval in Europe.
Puma Biotech (PBYI) Q1 Loss Narrows, Sales Miss, Stock Down
by Zacks Equity Research
Puma Biotechnology (PBYI) Q1 loss per share is narrower than the Zacks Consensus Estimate while sales misses the same.
Puma Biotech (PBYI) to Report Q1 Earnings: What to Expect?
by Zacks Equity Research
On the Q1 call, investor focus will be on sales of Puma Biotechnology's (PBYI) only marketed product, Nerlynx and updates on other label expansion studies on the drug.
Puma's Shares Fall This Year Post a Solid 2017: Here's Why
by Zacks Equity Research
Although the FDA approval for Puma's (PBYI) Nerlynx along with strategic alliances appreciates the stock in 2017, the CHMP's negative opinion on the cancer drug in 2018 affects its share price.
Puma Biotechnology (PBYI) Up 10.2% Since Earnings Report: Can It Continue?
by Zacks Equity Research
Puma Biotechnology (PBYI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Puma (PBYI) Q4 Loss Narrower Than Expected, Shares Down
by Zacks Equity Research
Puma (PBYI) posts narrower-than-expected loss in Q4. Revenues also surpass estimates supported by sales of the company's only marketed drug, Nerlynx.
What's in the Cards for Puma (PBYI) This Earnings Season?
by Zacks Equity Research
Contrary to nominal sales generated by Puma's (PBYI) only marketed drug Nerlynx last quarter, post its launch in August 2017, the candidate is likely to fetch higher revenues in Q4.
Is a Beat in Store for Horizon Pharma (HZNP) in Q4 Earnings?
by Zacks Equity Research
On Horizon Pharma's (HZNP) fourth-quarter 2017 earnings call, investors focus will be on the performance of its business units and key products.
What's in the Cards for Merrimack (MACK) in Q4 Earnings?
by Zacks Equity Research
Investors are likely to remain focused on Merrimack's (MACK) pipeline updates when it reports Q4 numbers, early next month.
What's in Store for Endocyte (ECYT) This Earnings Season?
by Zacks Equity Research
Endocyte (ECTY) is expected to provide updates on its pipeline candidates EC1169 and EC2629 during the fourth quarter 2017 earnings call on Feb 26.
Can Rhopressa's Approval Drive Aerie (AERI) in Q4 Earnings?
by Zacks Equity Research
Aerie (AERI) looks poised for a beat when it reports Q4 results (due on Feb 28) on the back of lead drug Rhopressa's approval.
Is a Beat in the Cards for Perrigo (PRGO) in Q4 Earnings?
by Zacks Equity Research
Perrigo's (PRGO) product purchases and launches in the Rx segment might boost sales in the coming quarters.